Sai Life Sciences Q1 FY27 Results: Dates and Estimates

Stock snapshot and what investors are tracking

Sai Life Sciences Ltd. (NSE: SAILIFE, BSE: 544306) is entering the June-quarter results season with its Q1 FY27 update scheduled for early August. The stock data shared shows the share price around ₹1,260 with a +0.32% move on BSE at 03 Jul, 04:01 PM, while another datapoint cites a current share price of ₹1,257.3. The same set of details also lists a 52-week high of ₹1,237.5 and a 52-week low of ₹776.2, and a “today’s low” of ₹1,260 in the snapshot.

The stock is widely followed because the company operates as an integrated CRDMO (Contract Research, Development and Manufacturing Organization), providing services across the pharmaceutical lifecycle. In the run-up to results, attention is on revenue momentum, margins, and how the company’s growth profile in FY26 carries into FY27.

Board meeting on August 6: what is on the agenda

Sai Life Sciences has announced that its Board of Directors will meet on August 6, 2026 to consider and approve the unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). The company has indicated that the results will include both standalone and consolidated figures.

This matters because the board meeting provides the formal timing anchor for the market, especially when multiple third-party “results window” references exist for July-August 2026. Investors typically watch for operational performance in the June quarter and management commentary on demand conditions across discovery and CDMO lines.

Trading window closure: compliance timeline

Alongside the results process, the company has closed its trading window for directors, officials, and designated persons from July 1, 2026 to August 8, 2026. The stated purpose is to prevent insider trading ahead of the earnings release and related discussions.

For market participants, this disclosure is mainly a governance and compliance indicator. It also signals that the company is within a structured financial reporting period, with restricted trading aligned to the board meeting and post-results window.

Earnings conference call on August 7

An earnings conference call is scheduled for August 7, 2026, from 4:00 PM to 5:00 PM IST. The call is slated to feature MD and CEO Mr. Krishna Kanumuri and Director and CFO Mr. Siva Chittor.

Calls like these are typically used to walk through quarterly numbers, explain segment-level movements, and address questions on margins, capacity additions, and capex funding. In this case, the call comes immediately after the board meeting date, keeping the information cycle tight for investors.

Recent quarterly trend: FY26 run-rate in reported numbers

The quarterly results table provided (figures in ₹ crore) shows a steady base through FY26, with net sales rising from ₹483.04 crore (Jun 2025) to ₹594.34 crore (Mar 2026). Over the same period, profit after tax (PAT) rose from ₹58.37 crore (Jun 2025) to ₹102.53 crore (Mar 2026), while adjusted EPS increased from ₹2.80 to ₹4.84.

Operating profit in this table ranges from ₹113.00 crore (Jun 2025) to ₹178.97 crore (Dec 2025), and interest costs fall to ₹6.16 crore by Mar 2026. Depreciation rises to ₹41.16 crore in Mar 2026, consistent with an asset base that appears to be scaling.

FY26 audited results: topline and profit expansion

The company reported audited financial results for the year ended March 31, 2026, approved by the Board in a meeting held on May 14, 2026. Revenue from operations for FY26 stood at ₹2,153.23 crore (converted from ₹21,532.26 million) compared with ₹1,642.05 crore in FY25 (converted from ₹16,420.48 million).

Profit for FY26 was ₹341.48 crore (from ₹3,414.81 million), up from ₹173.46 crore in FY25 (from ₹1,734.62 million). Basic EPS increased to ₹16.27 from ₹9.00. The disclosure also notes that the auditors’ report of Deloitte Haskins and Sells LLP was noted for the quarter and year ended March 31, 2026.

Q1 FY26 baseline and operational highlights disclosed earlier

For Q1 FY26, the company disclosed revenue from operations of ₹496 crore, EBITDA of ₹125 crore, and PAT of ₹60 crore. It also stated that it invested ₹134 crore in capital expenditure during Q1 FY26 and commenced work on building an additional 200 KL production capacity at Unit IV, Bidar, targeted to be ready by Q3 FY27.

These datapoints are relevant because they provide an earlier-quarter baseline for tracking the June-quarter trajectory and the near-term operational milestones tied to capacity expansion.

Street preview numbers cited: Q1 FY27 estimate range

A preview note included an estimate range for Q1 FY27:

• Revenue: ₹494–568 crore (range)
• PAT: ₹63–80 crore (range)

The same preview references that the framework uses a Q1 FY26 base of ₹506 crore revenue and ₹60 crore net profit, and cites a stock level of ₹1,252 with a market capitalisation figure of ₹26,284 crore and a P/E of 75.3 in that context.

Key facts table: dates, prices, and disclosed metrics

Market impact: what could move on the result day

In the near term, the market focus is likely to remain on reported revenue and profit versus the estimate ranges cited, along with any movement in margins. The snapshot also reflects wide variation in trading references and valuation metrics, including a cited P/E of 75.3 in the preview context.

Investors also track capacity additions and capex because they can influence depreciation and financing costs. The company’s earlier disclosure of work commencing on 200 KL additional capacity at Unit IV, Bidar, to be ready by Q3 FY27, provides a concrete operational timeline that can be revisited in management commentary.

Why the August disclosures matter

The August 6 board meeting and August 7 call create a defined window for the company to update the market on Q1 FY27 performance, provide consolidated and standalone numbers, and address progress on expansion and capital allocation. With FY26 showing a step-up in revenue from operations and profit in the audited results, Q1 FY27 becomes the first checkpoint for whether the company sustains that trajectory.

Conclusion

Sai Life Sciences is set to consider and approve its Q1 FY27 unaudited standalone and consolidated results on August 6, 2026, followed by an investor call on August 7. The next firm update for the market is the board-approved results and management discussion in that schedule.